**Supplemental Digital Content 1.** Flow-chart of eligible women for analysis of methylation at enrolment (n=248) and 6-month follow-up (n=128).

```
┌─────────────────────────────────────────────┐
│   498 HIV-infected women in the original paper │
└─────────────────────────────────────────────┘
                    │
                    ├──────────►  ┌─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┐
                    │             │ 234 women excluded because hrHPV-negative │
                    │             └─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┘
                    │
                    ├──────────►  ┌─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┐
                    │             │ 13 women excluded because of inadequate histology │
                    │             └─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┘
                    ▼
┌─────────────────────────────────────────────┐
│   251 hrHPV-positive women  tested for methylation │
└─────────────────────────────────────────────┘
                    │
                    ├──────────►  ┌─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┐
                    │             │ 3 women excluded because of not valid methylation │
                    │             └─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┘
                    ▼
┌─────────────────────────────────────────────┐
│ **248 hrHPV-positive women with valid methylation │
│   results**                                    │
└─────────────────────────────────────────────┘
                    │
                    ├──────────►  ┌─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┐
                    │             │ 58 women excluded because of lack of follow up │
                    │             └─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┘
                    ▼
┌─────────────────────────────────────────────┐
│   190 women with a second visit after 6 months │
└─────────────────────────────────────────────┘
                    │
                    ├──────────►  ┌─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┐
                    │             │ 53 women excluded because hrHPV-negative  and 1 │
                    │             │ because not tested                              │
                    │             └─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┘
                    ▼
┌─────────────────────────────────────────────┐
│   136 women re-tested for methylation          │
└─────────────────────────────────────────────┘
                    │
                    ├──────────►  ┌─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┐
                    │             │ 8 women excluded because of not valid methylation │
                    │             └─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─┘
                    ▼
┌─────────────────────────────────────────────┐
│ **128 women with methylation results at follow up** │
└─────────────────────────────────────────────┘
```

hrHPV, high-risk human papillomavirus; Ct, cycle threshold.

TABLE: Supplemental Digital Content 2. Spearman rank correlation coefficient between methylation levels of CADM1-m18, MAL-m1, and *MI*R124-2

by biopsy findings at baseline. 248 HIV-infected and high risk HPV-positive women, Kenya.

Biopsy findings	N	MAL-m1 vs CADM1-m18	MIR124-2 vs CADM1-m18	MIR124-2 vs MAL-m1
Normal	71	0.40	0.39	0.42
CIN1	84	0.42	0.30	0.38
CIN2+	93	0.58	0.63	0.73
Overall	248	0.56	0.55	0.60

CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.